METPRIDE 2 MG/500 MG TABLET
By Metpride
Rx
10 Tablet in a Strip

Composition
Glimepiride(2mg) + Metformin(500mg)

Manufacturer - Alkem Laboratories Ltd
Alkem Laboratories Limited, Devashish Building, Alkem House, Senapati Bapat Road, Lower Parel, Mumbai - 400 013.

Expires on or after
August, 2025

liver
When it comes to liver health, it is important to approach the use of METPRIDE 2 MG/500 MG TABLET with caution. Patients with liver disease should be careful when taking this medication, as dose adjustment may be necessary. It is advisable to consult your doctor before starting METPRIDE 2 MG/500 MG TABLET. Typically, the medication is initiated at a low dose for individuals with mild to moderate liver disease. However, it is not advisable to use METPRIDE 2 MG/500 MG TABLET in patients with severe liver disease. It is crucial to prioritize your liver health and seek proper medical guidance when considering the use of this medication.

kidney
METPRIDE 2 MG/500 MG TABLET should be used carefully in patients with kidney issues. Adjusting the dose may be necessary, and it is not recommended for severe kidney disease. Monitoring kidney function tests during treatment is advised.

alcohol
It is not safe to drink alcohol while taking METPRIDE 2 MG/500 MG TABLET.

driving
Caution while driving If experiencing low or high blood sugar symptoms, avoid driving when taking METPRIDE 2 MG/500 MG TABLET.

pregnancy
METPRIDE 2 MG/500 MG TABLET may not be safe to use during pregnancy, as animal studies indicate potential harm to the baby. Your doctor will consider the risks and benefits before prescribing this medication. Please consult your doctor.

breastfeeding
Caution is advised when considering breastfeeding while taking METPRIDE 2 MG/500 MG TABLET, as it is considered unsafe and may pose a risk of toxicity to the baby.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | ANTI DIABETIC |
Action Class | - |
₹8.12
Inclusive of all taxes
Content verified by

Dr. Mansi Chaudhari
MBBS - General Medicine
Last update on 01-Oct-2024